Alzheimer's Disease (AD)
Conditions
Keywords
Lymphaticovenous Anastomosis, cognitive function, therapeutic efficacy, Mechanism, Alzheimer's Disease
Brief summary
The aim of this clinical trial is to determine whether Lymphaticovenous Anastomosis can treat Alzheimer's disease，in AD patients aged 18-80.he main questions it aims to answer are: 1. Can Lymphaticovenous Anastomosis improve cognitive function, daily living ability, mood, or sleep status in patients with Alzheimer's dementia, demonstrating good therapeutic efficacy? 2. Does deep Lymphaticovenous Anastomosis lead to changes in peripheral blood biomarker levels, neuroinflammatory responses, and neuroimaging in patients with Alzheimer's dementia?
Interventions
PROCEDURELymphaticovenous Anastomosis
Lymphaticovenous Anastomosis (LVA) is an emerging super-microsurgical procedure pioneered by Professor Xie Qingping and his team, a group of Chinese microsurgery experts. This technique has been published in the official journal of the American Society of Plastic Surgeons (ASPS), confirming its effectiveness in improving the drainage function of the brain and reducing lymphatic pressure in deep brain tissues. By establishing an anastomosis between lymphatic vessels and veins in the neck, the surgery enhances the drainage of cerebrospinal fluid, alleviating the accumulation of toxins and waste within the brain, thereby easing the symptoms of Alzheimer's disease. Due to its significant contribution to the field of microsurgery, this innovative surgery has been selected as one of the Top Seven Advances in Microsurgery for 2022.
Sponsors
Shenzhen Bao'an People's Hospital
Shenzhen Kangning Hospital
Luo Xinxin
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. At least two deputy chief physicians or above, diagnosed with Alzheimer's dementia according to the DSM-5 diagnostic criteria; 2. Age between 18-80 years old; 3. The course of the disease is at least 1 year; 4. MMSE score ≤ 24 points; MoCA score \< 26 5. Brain MRI shows hippocampal atrophy; 6. Patients and their families agree to participate in this project for surgical treatment and sign an informed consent form.
Exclusion criteria
1. Individuals with contraindications for Lymphaticovenous Anastomosis; those allergic to anesthetics and contrast agents (indocyanine green); 2. Those unable to cooperate with cranial magnetic resonance imaging and scale testing; 3. Patients simultaneously suffering from schizophrenia, depression, bipolar disorder; 4. Patients with severe somatic diseases (such as cardiovascular, liver, kidney, gastrointestinal, etc.), infectious diseases, and immune system disorders; 5. Individuals with serious neurological diseases (such as epilepsy, cerebrovascular diseases, etc.), other types of dementia, mental retardation; 6. Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mini-Mental State Examination(MMSE) | half a year |
Countries
China
Contacts
Primary ContactXinxin Luo
Outcome results
None listed